Diagnostic Marker of Aggressive Cancer in Low Risk Prostate Cancer Patients
Description and applications
A 700+ patient retrospective study with up to 20 years of follow-up data has identified methylation of 3 genes to be an important biomarker (p<0.005) of aggressive prostate cancers that would regarded as low risk by current standards (PSA and Gleason Score).
Oliver T, Lorincz A, Cuzick J (2008). CHEMO-PREVENTION OF: PROSTATE CANCER: THE RATIONALE BEHIND DESIGN OF PILOT STUDIES. ANTICANCER RES vol. 28, (5C) 3428-3429.
Oliver T, Lorinez A, Cuzick J (2009). Prostate cancer prevention by short-term anti-androgens: the rationale behind design of pilot studies. Recent Results Cancer Res. vol. 181, 195-205
KeywordsProstate cancer, Biomarkers, Diagnostic
Wolfson Institute of Preventive Medicine
Get in touch with the Business Development Office email@example.com